• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    Physiologically-acceptable substituted 1,2-ethylenediamines and 1,3-propylenediamines, in free-base and in acid-addition-salt form, have highly pronounced and cardioselective beta -adrenolytic action, antiarrhythmic action and hypotensive action on administration to humans. The diamines are, more specifically, N-[3-aryloxy-2-hydroxypropyl]-N'-[1,3-(di-R3)-2,4-dioxypyrimid-6-yl] (ethylene or propylene)diamines wherein R3 is -H or lower alkyl and the aryl nucleus is either further unsubstituted, further monosubstituted or further disubstituted. The compounds are prepared, e.g, by reacting a corresponding N-[3-phenoxy-2-hydroxypropyl] (ethylene or propylene)diamine with a corresponding 6-chloropyrimidine-2,4-dione in a suitable medium containing an acid-binding agent. Such compounds are administered orally or parenterally in effective, but substantially non-toxic, doses either in substantially pure form, in virtually any standard dosage form or in combination with one or more other pharmacologically- and chemically-compatible drugs.
    公开号:SU793389A3
    申请号:SU782614700
    申请日:1978-05-15
    公开日:1980-12-30
    发明作者:Раабе Томса；Грэвингер Отто；Шольтхольт Иосеф；Шравен Экхард
    申请人:Кассела Аг (Фирма)；
    IPC主号:
    专利说明:

    application in the pharmaceutical industry. This goal is achieved by the described method of obtaining alkylenediamine derivatives of general formula 1 or their acid addition salts, the compound of general formula II wherein R and R2 have one of the above values and Z-CH-CH2; -HaE, -CH -CH, N / O and Nae is a halogen, is reacted with a compound of the general formula 7; {H - ((H2) ,, RS - is hydrogen, benzyl or carbobenzoxy; and n have the above values, followed by in free form or in the form of an acid additive salt in the case when Y is hydrogen, or if Y is benzyl or carbobenoxy, the compound obtained is subjected to catalytic hydrogenation hydrogen in an organic solvent at a temperature from room temperature to the boiling point of the solution, followed by isolation of the target product in free form or in the form of an acid additive salt. of the general formula G have an asymmetric C atom in the side al canolaamine chain and therefore may be in optically active forms. In the scope of the present invention, compounds of the general formula 1 may be understood as possible stereoisomers and optically active compounds of a mixture thereof, in particular the racemate. Inorganic and organic acids are suitable for the preparation of acid addition salts with compounds of the general formula. Suitable KISLOTs1MI yavl are, for example, hydrogen chloride, hydrogen bromide, naphthalenedisulphonic acid (1,5), phosphoric, nitric, sulfuric, .schaveleva, tartaric, lactic, acetic, salicylic, benzoic, formic, propionic, pi valine, diethylacetic, malonic succinic, pimelinic, fumaric, molineic, block, sulfamic, phenylpropionic, gluconic, ascor bino isonicotinic, methanesulfonic, p-toluene sulfonic, citric and adipic acid. Acid-additive salts can be obtained, as usual, by combining the components, expediently in a suitable diluent or dispersant. The reaction of the compounds of general formulas II and III is carried out in a suitable solvent or dispersant, in which the reaction components are dissolved or suspended. Such solvents or dispersants are selected from the group water, aromatic hydrocarbons, for example benzene, toluene, xylene; ketones, such as acetone, methyl ethyl ketone; halogenated hydrocarbons, such as chloroform, carbon tetrachloride, chlorobenzene, methylene chloride, ethers, such as tetrahydrofuran and dioxane; sulphoxides, such as, for example, dimethyl sulphoxide tert-acid amides, for example dimethyl formamide, and M-methyl pyrrolidone. in particular, polar solvents, for example alcohols, are used as solvents. Suitable alcohols are, for example, methanol, ethanol, isopropanol, tert-butanol, etc. Alcohols having 1-4 carbon atoms are preferred. The reaction is carried out at temperatures from the reflux temperature of the solvent or dispersant used. The reaction often proceeds at temperatures from 60 to 100 ° C. It may be advisable to use the starting compounds of general formula II in molar excess, 10-fold, or possibly more. When the compounds of the general formulas II and Ml are reacted, provided that in the general formula III Y is benzyl carbobenzoxy residue, the compounds of the general la, -CH-CH -N- (CH,), -NH-il 4 (la) R, T he is Y O where Y is benzyl or carbobenzoxy. The transfer of compounds of general formula 1a or their hydrohalides in compounds of general formula I occurs by cleavage of residue Y by known methods. A compound of general formula 1a or a hydrohalide thereof is dissolved or suspended in a suitable solvent, for example, an alkanol, an ether or a hydrocarbon, for example, ethanol, dioxane, toluene, xylene, etc., and is expediently treated with hydrogen in the presence of a suitable catalyst, for example, such as palladium / coal, at temperatures from room temperature () to the reflux temperature of the solvent used. After the catalyst is aspirated, a compound of the general formula I can be isolated. Example 1. 4.5 g of 2-n-butoxyphenylglycide ester together with 5.8 g
    N-6eH3HJi-N- D., 3-dimethyl-2, 4-dioxo-pyrimidyl (6) J ethylenediamine and 150 ml of ethanol is heated for 2 hours under reflux. It is then cooled and the solution is concentrated in vacuo. A gummy residue remains, which is dissolved in 150 ml of dioxane without further purification, followed by hydrogenation with Hj in the presence of Pd / C for 10 hours at 20 ° C. Then it is sucked off, the filtrate is concentrated and the residue is recrystallized once from toluene. In this way, N-3- (o-butoxyphenoxy) -2-hydroxypropyl -N-1, 3-dimethyl-2,4-dioxopyrimidyl- (6) -ethylene diamine is obtained; m.p. 129 ° C.
    Found,%: C 59.8; H 7.7; N 13.1. (C2 H32N40.
    Calculated.%: C 60.0; H 7.6; N 13.3.
    Yield 74% of theoretical.
    M-benzyl-M, 3-dimethyl-2, 4-dioxopyrimidyl (6) -ethylenediamine, which can be used as the starting material, can be obtained by reacting 1, 3-dimethyl-6-chloropyrimidi-Dione (2,4) with N-benzylethylenediamine in boiling toluene, wherein N-benzyl-N-1, 3-dimethyl-2, 4-dioxopyrimidyl (b) ethylene diamine is released as hydrochloride (m.p. with decomposition). From hydrochloride can be obtained using an aqueous soda solution free base; m.p. 112 ° C.
    Example 2.4.5 g of 2-p-butoxyphenylglycide ester together with 6.7 g of N-carboxybenzene-N-1, 3-dimethyl-2, 4-dioxopyrimidyl (6) -ethylene diamine in 150 ml of ethanol is heated for 2 hours with reverse a fridge. It is then cooled and the solution is concentrated in vacuo. A gummy residue remains, dissolved in 150 ml of dioxane without. further purification followed by hydrogenation with H2 in the presence of Pd / C for 10 hours at 20 ° C. The mixture is then filtered off with suction, the filtrate is concentrated and the residue is recrystallized once from toluene. In this way, N-3-o-oxytoxyphenoxy) -2-oxycapyl-N-1, 3-dimethyl-2, 4-dioxopyrimidyl (b) -ethylene diamine is obtained; m.p. 129 ° C.
    Found,%: C 59.7; H 7.7 / N 13.2.
    C2-I H32N405Calculated,%: C 60.0; H 7.6; N 13.3.
    Output 75% of theoretical.
    Example 3. 4.5 g of 2-p-butoxyphenylglycide ester together with 5.8 g of M-benzyl-N- | 1-3-dimethyl-2,4-dioxopyrimidyl (6) 3-ethylenediamine in 150 MP of ethanol is heated for 2 hours with reflux condenser. Then it is cooled and the solution is concentrated in vacuo. The remaining residue is dissolved in 150 ml of methanol, followed by hydrogenation with 50 Ah in the presence of Rene nickel for 5 hours at. Then sucked off
    The concentrate is concentrated and the residue is recrystallized once from toluene. In this way (o-butoxyphenoxy) -2-oxycipylJ-N-p, 3-dimethyl-2, 4-dioxopyrimidyl (b) ethylene diamine are obtained; m.p. 129 ° C.
    Found,%: C 59.8; H 7.5 / N 13.2.
     05Calculated,%: C 60.0; H 7.6; N 13.3.
    Yield 71% of theoretical. If the hydrogenation is carried out in one of the following solvents, the following yields are obtained,% of theoretical
    Ethanol78
    Toluene68
    Glycol monomethyl ether 68 Example 4.4.2 g of 2,3-dimethoxyphenylglycide ester together with 5.8 g of N-benzyl-N-L1,3-dimethyl-, 4-dioxopyrimidyl (6) ethylenediamine in 150 ml of ethanol is heated under reflux for 2 h. Then cooled and the solution concentrated in vacuo. The remaining residue is dissolved in 150 ml of methanol, followed by hydrogenation with H2 in the presence of Pd / C for 3 hours under reflux at boiling point. After that, it is filtered off with suction, the filtrate is concentrated and the residue is recrystallized once from toluene. Thus, (2,3-dimethoxyphenoxy) -2-hydroxypropyl-y-1, 3-dimethyl- 2, 4-dioxopyrimidyl is obtained (6) J-ethylenediamine; m.p. 146 ° C.
    Found,%: C 55.8; H 6.8, N 13.5.
    Cl9 23 N4 COMPLETED,%: C 55.9, H 6.9;
    N 13.7.
    Output 76% of theoretical. If hydrogenation is carried out
    at 70 ° C in ethanol or at 40-50 ° C
    in toluene then get the outputs 73
    or 70% of theoretical.
    Example 5. A solution of 4.5 g of 2-p-butrxyphenylglycide ester in 100 ml of ethanol is poured over 5 hours evenly in a refluxing solution of 5.7 g, 3-dimethyl-2, 4-dioxopyrimidil (6) J-ethylenediamine in 150 ml of ethanol and then heated under reflux for another hour. After that cool and the solution is concentrated
    in a vacuum. The remaining residue is recrystallized twice from toluene. In this way, N-3- (o-butoxyphenoxy) -2-hydroxypropyl -k, 3-dimethyl-2,4-dioxopyrimidyl (6) 3-ethylenediamine are obtained; m.p. 129 ° C.
    Found,%: C 59.9; H 7.6, N 13.4.
    C21 H32N4 05
    Calculated,%: C 60.0; H 7.6j. M 13.3.
    Output 80% of theoretical.
    Example 6.4.5 g of 2-p-butoxphenylglycide ester together with 15.0, g, 3-dimethyl-2, 4-DIOXOPY-rimidyl (6) J-ethylenediamine in 150 ml of ethanol is heated for 2 hours under reflux. The remaining residue is recrystallized three times in fractions from toluene.
    In this way, (o-butoxyphenoxy) -2-hydroxypropyl —N-1, 3-dimethyl-2,4-dioxopyrimidyl (6-ethylene diamine, mp 127-128 ° C.) is obtained.
    Found,%: C 59.7; H 7.4; N 13.7
    Cgi Hj-iN OffCalculated,%: C 60.0; H 7.6;
    N 13.3 ..,
    Yield 61% of the theoretical. Chromatography on a column can
    substance so clean to
    t
    F
    ,five
    at
    , with a molar residue, which is dissolved in 150 ml of dioxane, followed by hydrogenation with H, in the presence of Pd / C for 10 hours at 20 ° C. Then it is filtered off with suction, the filtrate is concentrated and the residue is recrystallized once from toluene. In this way, N-13h- {o-ethoxyphenoxy) -2-hydroxypropyl I, -N-l, 3-dimethyl-2,4-dioxopyrimidyl (6) 1-ethylenediamine are obtained, m.p. 129 ° C.
    Found,%: C 58.0; H 7.0; N 14.3.
    q9H28N40.
    Calculated,%: C 58.2; H 7.1; N 14.3 Yield 78% of theoretical. If, instead of dioxane, one of the following solvents is used in the hydrogenation, then the above outputs are obtained, in% of the theoretical:
    Table continuation
    Table continuation
    权利要求:
    Claims (1)
    [1]
    The invention of the method for producing alkylenediamine derivatives - the general formula I - (H 2 - CH - (H 2 -W- (CH 2) - - w 11 Lo R, (where R and R 2 independently of one another denote hydrogen halogen, trifluoromethyl, nitro, hydroxyl, phenyl , alkyl with 1-8 carbon atoms, alkenyl with 3 and 4 carbon atoms, alkynyl with 3 or 4 carbon atoms, cycloalkyl with the number of carbon atoms in the ring 5 or b, cycloalkenyl with the number of carbon atoms in the ring 5 or 6 alkoxy with 1- 8 carbon atoms, cycloalkoxy with the number of carbon atoms in the ring 5 or 6, alkenyloxy with 3-4 aTOMaiMH carbon, alkynyloxy with 3 or 4 at carbon ohms, phenethyloxy, benzyloxy, alkanoyl with 1-6 carbon atoms, alkoxyalkoxy with 3-8 carbon atoms, alkoxyalkyl with 2-6 carbon atoms, oxyalkoxy with 2-6 carbon atoms, the residue —NH — CO — Rg, and Kg means morpholino, piperidino or 1-pyrrolidinyl, alkanoylamino with up to 11 carbon atoms in the alkanoyl residue, ureido, uraido at position 3 monosubstituted with cycloalkyl with 5 or 6 carbon atoms, ureido at position 3 mono- or disubstituted with alkyl with 1-6 carbon atoms and / or alkenyl with 3 or 4 carbon atoms, R is hydrogen or alkyl with 1-4 carbon volumes n - the number 2 or 3, or their acid addition salts, comprising a compound of general formula I,
    where R and R2 have one of the above values and 2
    CH-CH,
    -CH-CH -, - NaE, / I
    or OH
    Hag - halogen,
    subjected to interaction with the compound of General formula III
    ABOUT
    AI.
    chnChON2) g, - sh. Lo
    where Y is hydrogen, benzyl or carbobenzoxy, R and p are as defined above.
    with the subsequent or separation of the target product in free form or in the form of an acid additive salt in the case when Y is hydrogen, or in the case when Y is benzyl or carbobenzoxy, the resulting compound is subjected to catalytic hydrogenolysis of hydrogen in an organic solvent at a temperature from room temperature to boiling point of the solvent followed by isolation of the desired product in free form or as an acid addition salt.
    Sources of information taken into account in the examination 1. Weigand-Hilgetag. Experimental methods in organic chemistry, M., Himi, 1968, p. 378.
    类似技术:
    公开号 | 公开日 | 专利标题
    SU793389A3|1980-12-30|Method of preparing alkylenediamide derivatives or their acid-additive salts
    SU1140687A3|1985-02-15|Method of obtaining carbostyrene derivatives or their pharmaceutically acceptable salts with acids
    US4059621A|1977-11-22|Substituted benzamido propanolamines
    EP0051879B1|1986-02-05|Substituted pyrimidines, their synthesis and compositions containing them, their use in medicine and intermediates for making them
    US4118417A|1978-10-03|Process for resolving cis-1-substituted phenyl-1,2-cyclopropanedicarboxylic acids
    US4766142A|1988-08-23|Poly-4-aminopyrrole-2-carboxamido derivatives and their use as antiuiral or antitumor agents
    US3974156A|1976-08-10|2-| methylmorpholine compounds
    CA1285934C|1991-07-09|Poly-4-aminopyrrole-2-carboxamido derivatives and process for their preparation
    US4251454A|1981-02-17|Benzylpyrimidines
    CS197300B2|1980-04-30|Method of producing new 1-/isoquinoline-1-one-2-yl and 1,2,3,4-tetrahydrobenzazepine-1-one-2-ylalkyl/ phenyl-et
    US20090149488A1|2009-06-11|Tetrahydroprotoberberine Compounds, the Synthetic Method and the Use Thereof
    EP0579614A1|1994-01-26|Imidazoacridines and their antineoplastic use.
    FR2763334A1|1998-11-20|Piperazino alkyl anthranilic acid amide
    US4714764A|1987-12-22|2-|-benzimidazole derivatives having antiviral activity
    FR2631827A1|1989-12-01|NOVEL | ARYL-5 TETRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THERAPEUTIC USE THEREOF
    SU845778A3|1981-07-07|Method of preparing 5-puenyl-1h-banzazepins or their salts
    EP0011372A1|1980-05-28|1-Acyloxyphenyl-1,2-diphenylalkene derivatives, processes for their manufacture and a pharmaceutical composition containing these derivatives
    SU890977A3|1981-12-15|Method of preparing pyridazinyl-hydrazones or their acid-additive salts
    US4268511A|1981-05-19|3-Amino|quinazoline-2,4-dione derivatives and their therapeutic applications
    Weller et al.1978|Carbon-13 nuclear magnetic resonance assignments of pactamycin and related compounds
    US3957785A|1976-05-18|Bβ-Pyrimidino-aminomethyl-10α-ergoline and 10α-methoxyergoline derivatives
    GB2101990A|1983-01-26|Isocarbostyril derivatives
    US4062891A|1977-12-13|N-formyl-2,3,5,6-dibenzobicyclo[5.1.0]octan-4-methylamine
    IE50035B1|1986-02-05|Hexahydro-trans-pyridoindole neuroleptic agents
    US3268533A|1966-08-23|4-aminophenylcyclopropyl ketones
    同族专利:
    公开号 | 公开日
    FI781461A|1978-11-17|
    BG28699A3|1980-06-16|
    GB1583428A|1981-01-28|
    SU841587A3|1981-06-23|
    AT359522B|1980-11-10|
    ZA782758B|1979-05-30|
    CS203005B2|1981-02-27|
    NL7804966A|1978-11-20|
    ATA342978A|1980-04-15|
    PL206810A1|1979-04-09|
    NZ187272A|1979-12-11|
    GR71668B|1983-06-20|
    SE7805260L|1978-11-17|
    IE780971L|1978-11-16|
    PL113674B1|1980-12-31|
    AU3610578A|1979-11-22|
    NO781635L|1978-11-17|
    US4216314A|1980-08-05|
    CA1085842A|1980-09-16|
    RO75870A|1982-12-06|
    DE2819629A1|1978-11-30|
    IT7823416D0|1978-05-15|
    BE867116A|1978-11-16|
    DK203078A|1978-11-17|
    AR224251A1|1981-11-13|
    EG13302A|1983-09-30|
    ES469895A1|1979-09-16|
    ATA343078A|1980-04-15|
    FR2391199A1|1978-12-15|
    LU77339A1|1979-01-19|
    PL113762B1|1980-12-31|
    JPS53141285A|1978-12-08|
    IT1158712B|1987-02-25|
    PT68044B|1979-10-24|
    AT359523B|1980-11-10|
    DD135489A5|1979-05-09|
    FR2391199B1|1981-07-24|
    PT68044A|1978-06-01|
    BG28700A3|1980-06-16|
    IE46895B1|1983-10-19|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    BE787103A|1971-08-04|1973-02-02|Pfizer|NEW PROPANOLAMINE DERIVATIVES AND PHARMACEUTICAL COMPOSITION CONTAINING|
    US4020071A|1973-12-20|1977-04-26|Cassella Farbwerke Mainkur Aktiengesellschaft|Derivatives of 1-phenoxy-3-amino-propan-2-ol|DE3023369A1|1980-06-23|1982-01-14|Boehringer Mannheim Gmbh, 6800 Mannheim|ARYLOXYPROPANOLAMINE, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS|
    DE3048487A1|1980-12-22|1982-07-29|Cassella Ag, 6000 Frankfurt|BASICLY SUBSTITUTED PYRIDAZINE, THEIR PRODUCTION AND THEIR USE|
    DE3131146A1|1981-08-06|1983-02-24|Boehringer Mannheim Gmbh, 6800 Mannheim|NEW HETEROARYLOXYPROPANOLAMINE, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS|
    JPS59225170A|1983-06-07|1984-12-18|Mitsui Toatsu Chem Inc|Aminopropanol derivative, its preparation, and cardio- selective agent for blocking beta-adrenalin action containing said compound|
    JPH0637479B2|1987-12-28|1994-05-18|三井東圧化学株式会社|Novel pyrimidine derivative, production method thereof and antiarrhythmic agent containing the same|
    US5308848A|1989-10-24|1994-05-03|Mitsui Toatsu Chemicals, Incorporated|Pyrimidinedione derivatives and antiarrythmic agents containing the same|
    US5008267A|1988-10-29|1991-04-16|Mitsui Toatsu Chemicals, Incorporated|Pyrimidinedione compounds, method of producing the same and antiarrythmic agents containing the same|
    JPH03173885A|1989-12-01|1991-07-29|Mitsui Toatsu Chem Inc|Pyrimidinedione derivative compound, production of the same compound and antiarrhythmic agent containing the same compound|
    JP2815218B2|1990-04-13|1998-10-27|三井化学株式会社|Pyrimidinedione derivatives and antiarrhythmic agents containing the same|
    JPH0413669A|1990-04-27|1992-01-17|Mitsui Toatsu Chem Inc|Novel pyrimidinedione derivative and antiarrhythmic agent containing the compound|
    DE4035599A1|1990-11-06|1992-05-07|Dresden Arzneimittel|NEW 5--URACILE, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS A MEDICINAL PRODUCT|
    WO2002092060A1|2001-05-11|2002-11-21|Endo Pharmaceuticals, Inc.|Abuse-resistant controlled-release opioid dosage form|
    WO2003084520A2|2002-04-05|2003-10-16|Euro-Celtique S.A.|Pharmaceutical preparation containing oxycodone and naloxone|
    EP1702558A1|2005-02-28|2006-09-20|Euro-Celtique S.A.|Method and device for the assessment of bowel function|
    US9271940B2|2009-03-10|2016-03-01|Purdue Pharma L.P.|Immediate release pharmaceutical compositions comprising oxycodone and naloxone|
    CA2918004C|2013-07-23|2018-11-20|Euro-Celtique S.A.|A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    LU77339A|LU77339A1|1977-05-16|1977-05-16|
    [返回顶部]